Cutaneous immune‐related adverse effects (irAEs) are becoming more apparent with the increasing use of immune checkpoint inhibitors (ICIs) in melanoma patients, dermatologists say. According to a Commentary in the British Journal of Dermatology, the PD‐1 inhibitors are now a first-line option in metastatic melanomas and also show significant potential in the treatment of advanced‐stage squamous and ...
Skin adverse events of PD-1 inhibitors may be marker of prognosis
By Michael Woodhead
17 Jul 2019